- Tickers in this article:
- NVAX
Drug developer Novavax to offer 6.8 million shares of common stock at $3.30 each; stock falls
11/20/09 - 10:36 AM EST
Biotech Stock Mailbag: FDA Playbook
Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.
11/20/09 - 06:01 AM EST
Vaccines On Horizon For AIDS, Alzheimer's, Herpes
'Golden era' could bring vaccines against AIDS, Alzheimer's and addictions within 5 years
11/17/09 - 01:48 PM EST
Judges: Seattle Biotech Can Pursue $23M Claim
- Tickers in this article:
- CTIC
Federal appeals court: Seattle biotech can pursue $23 million claim against former consultant
11/18/09 - 08:08 PM EST
U.S. Sees Low Demand for BioCryst Flu Drug
Peaking flu season could mean no need for further peramivir orders.
11/18/09 - 11:12 AM EST
Another Genzyme Drug Goes Kaboom: BioBuzz
Company halts development of kidney disease drug following poor test results.
11/18/09 - 08:05 AM EST
Vivus Seeks Faster ED Drug: Biobuzz
Company says ED drug met all goals in phase III study.
11/18/09 - 06:42 AM EST
Trading Higher in a Down Market
NEW YORK (TheStreet) -- Portfolio Manager David Peltier discusses two low-dollar stocks that are bucking the market trend on Tuesday.
11/17/09 - 01:15 PM EST
Genzyme's Termeer: Worst Biotech CEO of '09
Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.
11/17/09 - 12:31 PM EST
Isis Cholesterol Drug Effective, but Safety a Worry: BioBuzz
Mipomersen lowers cholesterol but not without liver side effects.
11/17/09 - 10:56 AM EST
InterMune Hep C Drug Hit With Liver Tox Worry: BioBuzz
Safety monitors force change to mid-stage study of ITMN-191
11/17/09 - 09:11 AM EST
Vical Will Be Added To Biotech Index, Shares Rise
- Tickers in this article:
- VICL
Vical shares rise after the company says it will be listed on Nasdaq biotech index Nov. 23
11/16/09 - 02:27 PM EST
Connect with TheStreet